Financial services and pharmaceuticals are two very different industries. I think one stock from each of these could prove to be excellent income stocks.
The two picks I’m referring to are abrdn (LSE: ABDN) and GSK (LSE: GSK). Here’s why I reckon investors should consider buying some shares.
abrdn
Since the firm underwent its re-brand, the shares have struggled. However, this hasn’t been down to a name and branding change. Underlying issues haven’t helped the firm. However, I think it’s now on the right course to provide steady investor returns at an attractive level.
Before I dive into that side of things, it’s worth noting that abrdn shares are down 25% over a 12-month period. They were trading for 217p at this time last year, compared to 162p at current levels. It’s worth mentioning that macroeconomic volatility hasn’t helped either.
Recent strategic moves could help boost abrdn shares, as well as investor returns. For example, the business announced just last month it is cutting 500 jobs. Most of this will be management-related roles it feels it doesn’t need. In addition to this, it is outsourcing technology, which could help bring costs down and improve efficiency.
Furthermore, acquisitions such as interactive investor in 2022, and exposure to the growing US healthcare market via adding Tekla Capital Management to its offering could bear fruit. The former has already helped boost performance.
The natural risk for me is that of continued macroeconomic volatility hurting inflows and revenues, which underpin investor rewards. Rising interest rates and inflation have wreaked havoc on global economies. This has hurt most financial services stocks so this is a major risk I’ll continue to monitor.
However, a dividend yield of 9% and the shares looking attractively valued on a price-to-book ratio of 0.5 makes the stock one to seriously consider for returns and growth.
GSK
Since GSK split and formed Haleon for its consumer healthcare division, it now focuses solely on developing drugs and treatments, which is a potentially hugely lucrative market in its own right.
The shares are up 13% over a 12-month period. They were trading for 1,456p at this time last year, compared to current levels of 1,654p.
The allure of GSK stems from its long and storied track record in the drug development business. Plus, its good financial and performance track record. Many of its drugs are leaders in their respective fields. In addition to this, it is making real headway towards becoming a major player in the vaccines market. This is primarily linked to heavy investment in recent years.
For me, the biggest issue that could hinder GSK shares and payouts is that of continued investment and failure to create drugs and vaccines that make it to market. This could hurt its performance, balance sheet, and investor sentiment.
However, a dividend yield of 3.5% and the shares trading on a price-to-earnings ratio of 13 make it very attractive. I am conscious that dividends are never guaranteed. Ultimately, I reckon the shares could continue to climb. Furthermore, I’d expect the level of return to do so as well.
The post 2 contrasting FTSE income stocks investors should consider snapping up! appeared first on The Motley Fool UK.
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy — and discover:
Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
How to potentially get paid by the weather
Electric Vehicles’ secret backdoor opportunity
One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
2 FTSE dividends that could be cut
£10,000 in savings? I’d aim for £633k in FTSE 100 shares and £25k a year of passive income
This 9%-yielding FTSE 250 dividend superstar looks like a hidden gem to me
Is this company a passive income dream?
An 8.7% yield but down 20%! Time for me to buy this forgotten FTSE cash cow?
Sumayya Mansoor has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
